Related Experiment Video
Updated: May 14, 2026
Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells
Published on: June 28, 2013
[Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases]
1Institut für Experimentelle Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg. t.eschenhagen@uke.de.
Insights
Personalized medicine offers new hope for cardiovascular diseases, using genetic testing and biomarkers for tailored treatments. While challenges remain, these approaches promise improved patient outcomes and safer therapies.
Area of Science:
- Cardiovascular medicine
- Genomics
- Personalized medicine
Context:
- Cardiovascular diseases (CVDs) significantly impact public health, with current treatments benefiting only a subset of patients.
- Advances in understanding genetic underpinnings of heart conditions are paving the way for tailored therapeutic strategies.
- Existing treatments for many CVDs have limitations, leading to a need for more effective and individualized approaches.
Purpose:
- To explore the potential of personalized medicine in managing cardiovascular diseases, from monogenic disorders to multifactorial conditions.
- To highlight the role of next-generation sequencing and induced pluripotent stem cells in disease modeling and therapeutic testing.
- To discuss the current and future applications of genetic testing and biomarkers in predicting cardiovascular risk and guiding therapy.
Summary:
- Personalized medicine, including mutation-specific treatments for monogenic heart diseases and biomarker-guided therapies for multifactorial CVDs, is emerging as a key strategy.
- Next-generation sequencing and induced pluripotent stem cell models enable precise disease identification and individualized treatment evaluation.
- Genetic analyses can optimize drug response prediction and minimize adverse effects, exemplified by warfarin and simvastatin therapy.
Impact:
- Personalized approaches hold significant promise for improving cardiovascular disease management and patient outcomes.
- Further research and development of novel methods are crucial to fully realize the value of personalized medicine in cardiology.
- Integrating genetic insights and biomarker data can lead to more effective and safer cardiovascular care strategies.
Abstract:
Improved therapy and prophylaxis of cardiovascular diseases have contributed to an increase in life expectancy like no other field of medicine. However, many cardiological diseases remain untreatable and standard therapies often work only in a minority of patients or cause more harm than benefit. Personalized approaches appear to be a promising solution. Monogenic heart diseases are paradigmatic for this approach and can in rare cases be treated mutation specifically. Overall, however, success remains limited. Next generation sequencing will facilitate the identification of mutations causing diseases. Cell culture models based on induced pluripotent stem cells open the perspective of individualized testing of disease severity and pharmacological or genetic therapy. In contrast to monogenic diseases genetic testing plays no practical role yet in the management of multifactorial cardiovascular diseases. Biomarkers can identify individuals with increased cardiovascular risk. Furthermore, biomarker-guided therapy represents an attractive option with troponin-guided therapy of acute coronary syndromes as a successful example. Individual responses to drugs vary and are partly determined by genes. Simple genetic analyses can improve response prediction and minimize side effects in cases such as warfarin and high doses of simvastatin. Taken together personalized approaches will gain importance in the cardiovascular field but this requires the development of better methods and research that quantifies the true value of the new knowledge.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Cardiomyopathy V: Interprofessional Care
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...